XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myelomaJoel G. Turner, Daniel M. Sullivan|Oncotarget|2016Cited by 89
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitorsJoel G. Turner, Daniel M. Sullivan|Journal of Hematology & Oncology|2016Cited by 84
CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex VivoJoel G. Turner, Daniel M. Sullivan|Journal of Cancer|2013Cited by 78
Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple MyelomaJoel G. Turner, Daniel M. Sullivan|Cancer Research|2020Cited by 21
A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and BortezomibPaul G. Richardson, Kenneth C. Anderson, Rachid Baz et al.|Blood|2010Cited by 7